NDLI: Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab.

Please wait, while we are loading the content...

Epithelial cells expressing cytokeratins-19 and bone marrow micrometastases in patients with breast cancer at the time of primary surgery: clinical outcome during long-term follow-up

Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab.

Effect of progesterone receptor status on maspin synthesis via nitric oxide production in neutrophils in human breast cancer.

Procedures for location of non-palpable breast lesions: a systematic review for the radiologist.

Phase II study of neoadjuvant anastrozole and concurrent radiotherapy for postmenopausal breast cancer patients.

Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients.

Reliability of frozen section in breast sentinel lymph node examination.

Effect of screening mammography on cumulative survival of Japanese women aged 40-69 years with breast cancer.

Three models for predicting the risk of non-sentinel lymph node metastasis in Japanese breast cancer patients.

Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer.

GeneSearch™ BLN Assay could replace frozen section and touch imprint cytology for intra-operative assessment of breast sentinel lymph nodes.

Gene delivery of cyclin-dependent kinase inhibitors p21Waf1 and p27Kip1 suppresses proliferation of MCF-7 breast cancer cells in vitro.

Year: 2014 Volume: 21 Issue: 4

Year: 2014 Volume: 21 Issue: 3

Year: 2014 Volume: 21 Issue: 2

Year: 2014 Volume: 21 Issue: 1

Year: 2013 Volume: 20

Year: 2012 Volume: 19

Year: 2011 Volume: 18

Year: 2010 Volume: 17

Year: 2009 Volume: 16

Year: 2008 Volume: 15

Year: 1999 Volume: 6

Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Ohzawa, Hideyuki Sakatani, Takashi Niki, Toshiro Yasuda, Yoshikazu Hozumi, Yasuo
Description	Country affiliation: Japan Author Affiliation: Ohzawa H ( Department of Breast and General Surgery, Jichi Medical University, Shimotsuke, Japan.)
Abstract	BACKGROUND: The effectiveness of neoadjuvant chemotherapy is evaluated on the basis of pathological responses and survival outcome, because achievement of a pathological complete response (pCR) is a good predictor of long-term survival. However, few studies have assessed the survival of breast cancer patients who received neoadjuvant chemotherapy including trastuzumab. METHODS: The records of 161 breast cancer patients who received neoadjuvant chemotherapy between January 2006 and December 2011 were retrospectively reviewed. The patients were categorized into 4 subgroups on the basis of the status of the estrogen receptor (ER), the progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). HER2-positive patients received trastuzumab-based regimens. Pathological responses and survival were analyzed on the basis of breast cancer subtypes. RESULTS: The pCR results obtained were: luminal A and B (ER and/or PR-positive, HER2-negative), 6.3 % (5/79 cases); luminal-HER2 hybrid (ER and/or PR-positive, HER2-positive), 25.0 % (5/20 cases); HER2-enriched (ER and PR-negative, HER2-positive), 63.0 % (17/27 cases); and triple-negative (ER and PR-negative, HER2-negative), 25.7 % (9/35 cases). Achievement of pCR was a good predictor of disease-free survival in the HER2-enriched group. Overall survival of patients with pCR was slightly, but not significantly, better in the HER2-enriched and triple-negative subgroups. CONCLUSION: Responses and survival after neoadjuvant chemotherapy including trastuzumab of patients with HER2-positive tumors differed among disease subtypes. Our findings suggest that disease subtype is an important determinant of the efficacy of neoadjuvant chemotherapy.
File Format	HTM / HTML
ISSN	13406868
Issue Number	5
Volume Number	21
e-ISSN	18804233
Journal	Breast Cancer
Language	English
Publisher	Springer
Publisher Date	2014-09-01
Publisher Place	Japan
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Oncology Antibodies, Monoclonal, Humanized Therapeutic Use Antineoplastic Combined Chemotherapy Protocols Breast Neoplasms Drug Therapy Mortality Adult Aged Aged, 80 And Over Administration & Dosage Metabolism Pathology Female Humans Lymphatic Metastasis Middle Aged Neoadjuvant Therapy Receptor, Erbb-2 Retrospective Studies Survival Analysis Trastuzumab Treatment Outcome Clinical Trial Journal Article
Content Type	Text
Resource Type	Article
Subject	Radiology, Nuclear Medicine and Imaging Pharmacology (medical) Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer.

Trastuzumab for gastric cancer treatment. (Part 2)

Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis.

Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research.

Predicting the efficacy of trastuzumab-based therapy in breast cancer: Current standards and future strategies☆

Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.

Pathological response and survival after neoadjuvant therapy for breast cancer: a 30-year study.

Adjuvant trastuzumab therapy for HER2-positive breast cancer.

Neoadjuváns szisztémás terápia emlorákban.

Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab.

Similar Documents

High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer.

Trastuzumab for gastric cancer treatment. (Part 2)

Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis.

Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research.

Predicting the efficacy of trastuzumab-based therapy in breast cancer: Current standards and future strategies☆

Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.

Pathological response and survival after neoadjuvant therapy for breast cancer: a 30-year study.

Adjuvant trastuzumab therapy for HER2-positive breast cancer.

Neoadjuváns szisztémás terápia emlorákban.

Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab.